"Many drugs fail the phase 2 trial because of safety or side effect issues. Well this isn’t much of a risk with nnz2256. It is human derived and has shown no safety or side issue concerns at all."
I accept the phase 1 data showing NNZ-2256 is safe at doses tested there, but the whole 'natural' argument is a furphy. Take a look at the safety profile of IGF-1 - which is the natural molecule in which glypromate is an active site (NNZ-2256 is an analogue of glypromate). Google: 'igf-1 clinical trial outcomes' and you'll soon see that natural doesn't equal safer (or more effective).
And don't get me started on animal models being an accurate predictor for human applications. At last count, there were 127 different ways to cure type 1 diabetes in the main mouse model. Hasn't really translated too well to humans.
NEU Price at posting:
12.0¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)